Evaluation of Antimalarial Drugs in Indonesia, 1981 - 1995 by Tjitra, E. (Emiliana) et al.
EVALUATION OF ANTIMALARIAL DRUGS IN INDONESIA, 1981 - 1995 
Emiliana Tjitra', Suriadi Gunawan', Ferdinand Laihad", Harijani Marwoto', 
Sekartuti Sulaksono', Sumarjati Arjoso', Thomas L Richie"' dan Novianty Manurung"' 
EVAL UASI OBA T ANTIMALAM DI INDONESIA, 1981 - 1995 
Telah dilakukan evaluasi obat-obat antimalaria in-vitro dun in-vivo untuk menentukan pola 
resistensi dun memanfaatkan data ini untuk melakukan sistem pengamatan yang efektiJ Semua 
penelitian pengobatan dun pencegahan malaria di lapangan dun rumah sakit dalam kurun waktu 1981 
- 1995 ditelaah. 
Pertama kali kasus resistensi P. falcipamm terhadap klorokuin ditemukan di Kalimantan Timur 
pada tahun 1973, dun telah menyebar ke seluruh (27) propinsi Indonesia dengan derajat RI - RIII. 
Pada saat in;, resistensi RIII telah didapatkan di 20 propinsi, sedangkan pada tahun 1981-1985 hanya 
di 4 propinsi. Kasus malaria vivaks resisten klorokuin dilaporkan pertama kali dari Sumatera Utara 
(P. Nias) pada tahun 1991, dun kemudian ditemukan di Irian Jaya (41%), Sumatera Utara (13%), 
Nusa Tenggara Timur (8%), Sulawesi Utara (2%) dun Jakarta (laporan kasus yang didapatkan dari 
transjiusi darah). h4alaria falsiparum yang tercatat resjsten suyadoksin-pirimetamin didapatkan di I I 
propinsi dengan derajat RI - RII. P. falcipamm resisten in-vitro juga didapatkan terhadap kina (6 
propinsi), mejlokuin (5 propinsi) dun amodiakuin (4 propinsi). Beberapa obat antimalaria baru 
(mejlokuin, halofantrin dun derivat artemisinin) telah diteliti dun ternyata efekt~y untuk pengobatan 
malaria tanpa komplikasi. Penelitian pencegahan menunjukkan angka pencegahan untuk klorokuin 
41-92%, sulfadoksin- pirimetamin 98%, primakuin 89-92%, doksisiklin 99% dun meflokuin 100 %. 
Efek samping obat-obat antimalaria tersebut umumnya ringan. 
Di Indonesia, penyebaran malaria falsiparum resisten klorokuin RIII dun malaria falsiparum 
resisten multidmg merupakan masalah kesehatan masyarakat yang serius dun tantangan dalam 
pengobatan. Demikian pula kehadiran malaria vivaks resisten klorokuin menimbulkan masalah baru 
yang lain. OIeh sebab itu obat-obat antimalaria yang didistribusikan sebaiknya dikernas per paket 
untuk dosis obat pengobatan yang lengkap dengan keterangan cara minum obat yang jelas. Dengan 
demikian dapat dicegah pemberian dosis pengobatan yang-tidak cukup dun berkembangnya resistensi 
obat. Selama obat antimalaria baru belum tersedia di Indonesia, perlu dilakukan penelitian perbaikan 
ejkasi obat antimalaria yang sudah ada. Obat pencegahan alternatifyang aman dun efektif untuk 
anak-anak, ibu hamil dun menyusui juga perlu diteliti. 
INTRODUCTION smaller islands. There are 27 provinces, 
241 districts and 67,033 villages with a 
Indonesia is an archipelago consisting total population of 195.3 million in 1994 
of six main islands and 13,767 (Figure 1)'. 
* National Institute of Health Research and Development, Ministry of Health, Jakarta. 
** Directorate General of Communicable Disease Control & Environmental Health, Ministry of Health, Jakarta. 
*** Naval Medical Research Unit No 2, Jakarta. 
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Malaria remains a major public health 
problem, particularly outside of Java-Bali, with 
gromnce-wide Parasite Rates of 4.1 - 5.2% and 
Siide Positivity Rates of 29.2 - 44.3% during 
the period 1989 to 19931J. 
Since malaria vaccine is not available, 
management of the disease is the most 
important activity to control malaria. To support 
disease management, the Indonesian Ministry of 
Health has recommended rational malaria 
treatment policy that is based on the national 
malaria control programme. 
Chloroquine is the standard antimalarial 
drug for chemoprophylaxis, clinical malaria 
treatment and the blood schizontocide 
component of radical treatment. Sulfadoxine- 
pyrimetharnine and quinine are used as 
alternative antimalarial drugs for radical 
treatment of falciparum malaria in chloroquine 
resistant areas. Parenteral quinine is a 
life-saving antimalarial drug for severe and 
complicated malaria. Primaquine is a 
supplement to standard antimalarial drugs for 
radical treatment. Supportive therapy is given 
depending on clinical manifestations of organ 
dysfunction4. 
Several new antimalarial drugs, meflo- 
quine, halofantrine and artemisinin derivatives 
have been studied for the treatment of 
falciparum malaria, vivax malaria and severe or 
complicated malaria, in preparation for 
providing alternative antimalarial drugs. 
Treatment failure may be due to the 
increasing problem of drug resistance, 
Resistance to antimalarial drugs, especially 
chloroquine, has become a serious problem in 
case management throughout Indonesia. 
Collection of baseline data and an appropriate 
monitoring system for drug efficacy and 
resistance are required for reassessment and 
revision of national guidelines for malaria 
treatment. 
A11 evaluations of antimalarial drugs 
during the period 1981 to 1995 in Indonesia are 
reviewed in this paper to determine the pattern 
of drug resistance and to create a data base for 
an effective monitoring system and revise 
treatment guidelines. 
DEFINITION AND ASSESSMENT O F  
DRUG RESISTANCE 
In malaria, drug resistance is defined as 
the ability of a parasite strain to sunive andlor 
to multiply despite the administration and 
absorption of a drug given in doses equal to or 
higher than those usually recommended but 
within the limits of tolerance of the subject?. 
This definition is commonly applied to the 
iesistance of Plasmodium falciparum to the 
blood schizontocides. It has been extended to 
other species of malaria parasites such as P. 
vivax. 
The susceptibility of P. fa/ciparum to 
chloroquine and other antimalarial drugs was 
assessed by in-vitro and in-vivo sensitivity 
testing. Previously, the macrotest was used for 
in-vitro sensitivity testing of P. falciparum to 
chloroquine. Since 1984, the microtest has 
replaced the macrotest for testing chloroquine, 
sulfadoxine-pyrimetharnine, quinine, amodia- 
quine and mefloquine. Interpretation was made 
according to the WHO guideline (Table 
In most cases, field tests (28 days) were 
performed for in-vivo sensitivity testing. The 
resistance grading system is based on the 
response to normally recommended doses of 
chloroquine (25 mg baselkg bw in three days). 
This grading is also used for other blood 
schzontocides. The response of the parasites to 
blood schizontocides ranges from S to RIII 
(Table 2)5. 
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Table 1. Concentration of several blood schizontocidal drugs indicating 
in-vitro P. falciparum resistance6,'. 
Table 2. Grading of in-vivo resistance of asexual parasites of P. falciparum 
to blood schizontocidal drugss. 
The blood concentration of chloroquine P. vivax is based on the whole blood Minimal 
adequate for treatment has not yet been firmly Effective Concentration (MEC) of chloroquine. 
established. Currently, chloroquine resistance to A viable asexual parasitaemia of P. vivax with 
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>= 100 nglml chloroquine plus desethyl- 
chloroquine in whole blood demonstrates 
resistance8. 
DRUG SENSITIVITY MONITORING 
SYSTEM 
Since 1979, in-vitro and in-vivo drug 
sensitivity assays have been conducted in the 
major foci of suspected chloroquine resistance 
areas by the Subdirectorate of Malaria Control 
and by Local Health Authorities. Data obtained 
serve as an early warning of emerging problem 
of drug failure. The results of other field and 
clinical studies undertaken by the National 
Institute of Health Research and Development, 
by the Faculty of Medicine of the University 
of Indonesia and by the Naval Medical 
Research Unit 2 Jakarta have been very useful 
in supporting or clarifying preliminary 
reports and in early detection of treatment 
failures. 
In recent years, studies of alternative drugs 
such as mefloquine, halofantrine and 
artemisinin derivatives have been performed. 
Studies on new antimalarial drugs regimens, 
such as chloroquine plus doxycycline, are being 
camed out. 
EMERGENCE AND SPREADING OF 
DRUG RESISTANCE 
The first evidence of P. falciparum 
resistant to 4-aminoquinolines was noted from 
Venezuela (1959) and Columbia (1960), in 
South America9. The first case reports of 
recurrence of P. v ivm parasitaemia after various 
doses of chloroquine were reported from Papua 
New Guinea (1989-1992)1@14. It was then 
reported from other countries including 
Indonesia. 
CHLOROQUINE RESISTANCE 
According to the policy of the Indonesia 
Ministry of Health, chloroquine (4quinoline- 
amino group) is used as first line treatment. The 
first case of chloroquine resistant P. falciparum 
infection was reported from Kutai - East 
Kalimantan in 197315. Thereafter (1974-1979) 
more cases have been recorded from East 
Kalimantan and Irian JayaI5-17. 
During 1981 - 1995, in-vitro sensitivity 
testing of P. falciparum to chloroquine had been 
performed in 24 provinces, except in West 
S-umatera, South Sumatera and DI-Yogyakarta 
provinces (Annex 3). All of the 24 provinces 
had resistant cases, although resistant cases 
from DKI-Jakarta and Bali were imported cases. 
The number of samples tested per province 
ranged from 3 to 183 isolates in 1981-1985, 1 to 
62 isolates in 1986-1990, and 1 to 159 isolates 
in 1991-1995. The percentage of resistant cases 
in 1981-1985, 1986-1990 and 1991- 1995 were 
11 - 100 %, 11 - 100 %, and 23 - 100 %, 
respe~tively'"~"'~ (Table 3). 
Twenty five of the 27 provinces (except 
central Kalimantan and Bali) camed out 
in-vivo sensitivity testing of P. falciparum to 
chloroquine. Only West Java has not reported 
any resistant cases (Table 4). The numbers of 
patients examined per province in 1981-1985, 
1986-1990 and 1991-1995 were 1 - 26 cases, 2 - 
105 cases, and 1 -214 cases, respectively. Of 
those cases, 4 - 100 %, 10 - 100 %, and 12 - 100 
% were resistance cases at level of RI - RIII. 
Currently, RI, RI1 and RIII resistance affects 19, 
21 and 20 provinces compared to 8, 6 and 4 
provinces in 1981-1985, and 13, 17 and 14 in 
1986- 199016,28,3038-50 (Table 5). 
Evaluation of antimalarial ........................ Emiliana Tjitra et al 
Table 3. In-vitro P.fa1ciparum resistant to chloroquine in Indonesia, 1981 - 1995'6v2M2. 
percent by total number of provinces (27) 
** percent by number of provinces tested. 
Table 4. Percentage of P. falciparum resistant to chloroquine in Indonesia, 1981 -199516.2"R3650. 
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Table 5. In-vivo P. falcipurum resistant to chloroquine in Indonesia, 1981 - 19951L.2v0JL50. 
percent by total number of provinces (27) 
** percent by number of provinces tested 
*** percent by number of provinces reporting resistance. 
Combining in-vitro and in-vivo results, the 
overall number of provinces reporting P. 
falciparum resistance to chloroquine was 27 
provinces. In 3 provinces (West Java, Central 
Kalimantan and Bali) only in-vitro resistance 
was found, and another 3 provinces (West 
Sumatera, South Surnatera and DI-Yogyakarta) 
only reported in-vivo resistance. The other 21 
provinces reported both in-vitro and in-vivo 
resistance. Almost all levels of resistance were 
present throughout Indonesia. 
The first case of chloroquine resistant P. 
vivax was reported from Nias island - North 
Sumatera in 1991". In the last five years 
(1991-1995), documented chloroquine resistant 
vivax malaria was present in 5 of 7 provinces 
tested. The number of patients examined per 
province was 1-126. The resistant cases were 4 1 
% in Irian Jaya (Arso, Oksibil, Nabire and 
Timika), 13 % in North Sumatera (Nias), 8 % 
in East Nusa Tenggara (Sikka) and 2 % in 
North Sulawesi (Tomohon and Lembe). 
Another resistant case acquired by blood 
transfusion was reported from DKI- Jakarta. No 
resistant cases were found in Central Javz and 
West Nusa Tenggara. Most of the resistant cases 
were RI resistance (Table 6, and Table 7)48,5"4. 
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Table 6. Percentage of P. v i v a  resistant!to chloroquine in Indonesia, 1991 -19954cw4. 
Table 7. In-vivo P. v i v a  resistant to chloroquine in Indonesia, 1991 - 199548ss4. 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
'+ ,,, ,,, , , , ,  
Number of provinces tested ( % )* 
Number of samples tested per province (range) 
Number of provinces reporting resistance ( % )** 
Percentage of resistant cases (range) 
Cumulative number of provinces reporting resistance (%)* 
94 -95 
7 (26) 
1 - 126 
5 (71) 
2 -41 
5 (19) 
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SULFADOXINE-PYRLMETHAMINE 
RESISTANCE 
Sulfadoxine-pyrimethamine combination 
is recommended as a second line drug. Since 
1979, P. falciparum resistant to this drug has 
been reported2'. Thereafter, only few studies 
have been performed. 
During 198 1-1995, in-vitro sensitivity 
testing of P. falciparum to sufadoxine- 
pyrimethamine was performed in 13 provinces. 
Eleven provinces reported resistance: Aceh (67 
YO), North Sumatera (100 %), Riau (80 %), and 
Lampung (100 %) in 1981-1985; Central Java 
(22 and 71 YO) in 1981-1985 and 1986-1990; 
East Kalimantan (85 and 100 %) in 1986-1990 
and 1991-1995; East Timor (33 %) in 
1986-1990; North Sulawesi (60 %) and Central 
Sulawesi (50 YO) in 1991-1995; South Sulawesi 
(58 %) in 1981-1985; and Irian Jaya (81 and 82 
%) in 1986-1990 and 1991-1995. The other 
provinces, Bengkulu and DKI-Jakarta, had not 
reported resistance (Annex 5). The number of 
samples tested per provinces in 1981-1985, 
1986-1990, and 199 1- 1995 ranged from 2 to 38 
isolates, 1 and 29 isolates, and 1 and 77 isolates, 
respectively. The percentage of those resistant 
cases were 58-100 %, 22-100 % and 50-85 %, 
respectively (Table 8)16,3134-9.41-2.45,55-6 
In-vivo sensitivity testing of P. falciparum 
to sulfadoxine-pyrimetharnine was carried out 
in 9 provinces (Aceh, North Sumatera, Riau, 
Lampung, Central Java, East Timor, South 
Sulawesi, South-East Sulawesi and Irian Jaya) 
in 19m-1985. The number of patients examined 
per provinces was 1 - 119. Four provinces: 
Central Java, East Timor, South Sulawesi and 
Irian Jaya reported resistances of, respectively, 
12 % (141119) (RI-MI), 100 % (111) (RI), 2 % 
(1162) (RII), and 2 % (1141) (RII) (Table 9 and 
~ ~ b l ~  1 o)l6,44'5.57-9 
Combining in-vitro and in-vivo results, the 
total number of provinces reporting P. 
falciparum resistance to sulfadoxine-pyri- 
methamine was 11 out of the 14 provinces 
where tests were performed. Seven provinces 
only reported resistance by in-vitro test and the 
other 4 provinces reported resistance by both 
in-vitro and in-vivo tests at level of RI - RII. Of 
the 3 provinces reporting no resistance, 2 
provinces (Bengkulu and DKI-Jakarta) only 
conducted in-vitro sensitivity test and 1 
province (Southeast Sulawesi) only in-vivo 
sensitivity test. 
QUININE RESISTANCE 
Quinine is a life-saving antimalarial for 
malaria treatment. Until recently, there has been 
no reported in-vivo quinine resistance by 
falciparum malaria. However, several isolates 
have shown in-vitro resistance. 
In-vitro sensitivity testing of P. falciparum 
to quinine was performed during 1981-1985, 
1986-1990 and 1991-1995 in 4, 8 and 6 
provinces, with the number of isolates tested per 
province ranging from 1 to 17, 1 to 3 1, and 1 to 
132 isolates. In-vitro resistance was reported 
from West Java (one case in 1981-1985), 
Central Java (one case in 1981-1985), East 
Kalimantan (3 % or 2/60 in 1991-1995), East 
Nusa Tenggara (one case in 1981-1985). 
Central Sulawesi (25 % or 114 in 1991-1995) 
and Irian Jaya (29 % or 5/17 in 1981-1985). No 
resistance isolates were found in Riau, 
Bengkulu, DKI-Jakarta, East Timor, North 
Sulawesi, and South Sulawesi (Table I1 and 
~ ~ b l ~  12)16,34-9.41-2.45.60-1 
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Table 8. In-vitro P. falciparum resistant to sulfadoxine pyrimethamine in Indonesia, 
1981 - 199516.31.349.41-2.45,SSb 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
Table 9. Percentage of P. falciparum resistant to sulfadoxine-pyrimethamine in Indonesia, 
1981 - 1995164.55.57-9 
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Tabel 10. In-vivo P.falciparum resistant to sulfadonine-pyrimethamine in Indonesia, 
1981 - 1995~6~44~~~s~7-9 
* percent by total number of provinces (27) 
** percent by number of provinces tested 
*** percent by number of provinces reporting resistance. 
Of the 12 provinces tested, only 6 
provinces (West Java, Central Java, East 
Kalimantan, East Nusa Tenggara, Central 
Sulawesi and Irian Jaya) presented in-vitro P. 
falciparurn resistance to quinine. After 
198 1 - 1985, 3 provinces which have reported 
in-vitro resistance (West Java, Central Java and 
Irian Jaya) no longer reported resistance cases. 
In East Kalimantan where no resistance was 
present in 1986-1990, in-vitro resistance was 
reported in 1991-1995. 
SENSITIVITY OF OTHER BLOOD 
SCHIZONTOCIDES 
Amodiaquine resistance 
Amodiaquine is a 4 amino-quinoline 
antimalarial drug. This drug should be at least 
as effective as chloroquine. In Indonesia, 
amodiaquine is not available and has never been 
used. However, several in-vitro P. falciparurn 
sensitivity tests to this drug have been 
performed. 
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Table 11. Percentage of in-vitro P. falciphrum resistant to quinine in Indonesia, 
1981 - 1995~6J49.41-1,4~.~ 
Table 12. In-vifro R falciparum resistant to quinine in Indonesia, 
1981 - 199~16JC9~41-lv4iWl 
percent by total number of provinces (27) 
** percent by number of provinces tested. 
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In 1981-1985, only Irian Jaya was tested 
(5 samples). However in 1986-1990, 5 
provinces @KI- Jakarta, East Kalimantan, East 
Timor, South Sulawesi and Irian Jaya) were 
tested with the number of samples tested 
ranging from 1 - 27. Only one province (East 
Kalimantan) was tested (57 samples) in 
1991-1996. 
Of the 5 provinces tested, 4 provinces 
(East Kalimantan, East Timor, South Sulawesi 
and Irian Jaya) had resistance to amodiaquine 
(12 - 100 %). However, previously (198 1-1985), 
no amodiaquine resistance was found in Irian 
Jaya (Table 13 and Table 14)1634-5,42"'. 
Mefloquine resktance 
Mefloquine, a synthetic 4quinoline 
methanol, is a relatively new antimalarial drug. 
This drug has not yet been registered in 
Indonesia. Since 1982, several in-vitro and 
in-vivo P. falciparum sensitivity to this drug has 
been performed. 
Table 13. Percentage of in-vitro P. falciparum resistant to amodiaquine in Indonesia, 
1981 - 19951~C5,a,61. 
Table 14. In-vitro P. falciparum resistant to amodiaquine in Indonesia, 1981 - 199516,3C542961. 
percent by total number of provinces (27) 
** percent by number of provinces tested. 
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In-vitro sensitivity testing of P. falcipapm 
to mefloquine was run in 10, 13 and 6 
provinces, with the number of samples tested 
ranging from 2 to 35, 1 to 60, and 1 to 145, in 
1981-1985, 1986-1990 and 1991-1995. There 
were 2 (Central Java and Irian Jaya), 3 (East 
Nusa Tenggara, East Timor and Irian Jaya) and 
1 (East Kalimantan) provinces with respectively 
12-20%, 2.17% and 3% resistant cases in 
1981-1985, 1986-1990 and 1991-1995 (Table 
15 and ~ ~ b l ~  16) 16.3234-9.42 >7.60.2 
In-vivo sensitivity testing of P. falciparum 
to mefloquine (15 mgtkg bw, single dose) was 
performed in 2 (Aceh and East Kalimantan) and 
1 (East Kalimantan) provinces. The numbers of 
patients examined were respectively 19 and 23, 
and 14 in 1986-1990 and 1991-1995. No 
resistant cases were found in these tests (Table 
15 and Table 17)32"2-3. 
Combining in-vitro and in-vivo results, of 
the 18 provinces tested, 5 provinces (Central 
Table 15. Percentage of P. foLciparum resistant to mefloquine in Indonesia, 
1981 -199dJ102J49.a.~,s7~'.UU 
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Java, East Kalimantan, East Nusa Tenggara, Halofantrine resistance 
East Timor and Irian Jaya) presented only 
- - 
in-vitro P. falciparum resistance to mefloquine Halofantrine, a phenanthrene-methanol, is (2 - 20 %). Central Java in 1981-1985 and Irian 
a relative new antimalarial drug. This drug also 
Jays 1981-1990 mefloquim has not yet been registered in Indonesia. Since 
resistance, but there after no resistance was 
E~~~ mimantan mefloauine 199 1, several in-vivo P. falciparum and P. vivax 
resistance in 1991-1995 ~ a s t  Nusa sensitivity tests to this drug have been 
Tenggara in 1986-1990 (Table 15). performed. 
Table 16. In-vitro P. falcipurum resistant to mefloquine in Indonesia, 
1981 - 1995102~4-9.a.4s.n~w2 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
Table 17. In-vivo I? falcipurum resistant to mefloquine in Indonesia, 
1986 - 199516762J. 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
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In-vivo sensitivity tests of P. falciparum to 
halofantdne (500 mg 6 hourly with a total 
dosage of 1500 mg) were performed in East 
Kalimantan, North Sulawesi and Irian Jaya 
province with numbers of patients examined 63, 
59 and 36 respectively. Of the 3 provinces 
tested, East Kalirnantan and North Sulawesi 
reported resistant cases of 2 % and 12 % at RT 
level (Table 18 and Table 19 )35d.M. 
In-vivo sensitivity test of P. v i v a  to 
halofantrine were performed also in North 
Sulawesi and Irian Jaya province with the 
numbers of patients examined 44 and 21. RI 
resistance (5 %) was found only in North 
Sulawesi (Table 18 and Table 1 9)36.a". 
Artemisinin derivatives recurrence 
Artemisinin, a sesquiterpene-lactone- 
peroxide, is developed from Chinese traditional 
medicine. This drug and its derivatives (i.e: 
artesunate aid artemether) possess a powerful 
antimalarial activity and low toxicity. No 
resistance to this drug has yet been 
demonstrated. It is not yet commercially 
available in Indonesia. 
Table 18. Percentage of in-vivo P. falcipwum and P. vivax resistant to halofantrine in 
Indonesia, 1991 -19953Hu'. 
Table 19. In-vivo P. fakiporurn and P. v i v a  resistant to halofantrine in Indonesia, 
1991 - 199SJMuS. 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
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In-vivo sensitivity testing of P. falciparum 
(in uncomplicated falciparum malaria) to 
artesunate (600 mg in 5 days) was performed in 
East Kalimantan province. The number of 
patients examined was 10, with 40 % showing 
recurrence (late RI pattern) (Table 20 and Table 
2 
In-vivo sensitivity testing of P. falciparum 
(in uncomplicated in-vitro chloroquine resistant 
falciparum malaria) to artemether (480 mg in 5 
days) was performed in Irian Jaya province. The 
number of patients examined was 3 1, with 10 % 
showing recurrence (late RI  att tern)^'. 
MULTIDRUG RESISTANCE 
Falciparum malaria multidrug (more than 
one drug) resistance to chloroquine andlor 
sulfadoxine-pyrimethamine and lor quinine 
cases have been noted since 197926J9. 
During 1991 - 1995, in-vitro sensitivity 
tests of P. falciparum to several antimalarial 
drugs (chloroquine, sulfadoxine-pyrimethamine, 
quinine, amodiaquine and mefloquine) were 
performed in 4 provinces. The number of 
isolates tested ranged between 20 and 80 with 
multidrug resistance found in 84 %, 49 %, 40 % 
Table 20. Percentage of in-vivo P. falciparum recurrent to artemisinin derivatives in 
Indonesia, 1991 -1995M. 
Table 21 In-vivo P. falciparum recurrence to artemisinin derivatives in Indonesia, 
1991 - 199!?ia. 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
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and 11 % in East Kalimantan, Irian Jaya, Nqrth 
Sulawesi and East Timor, respectively. 
Combined resistance to chloroquine and 
sulfadoxine-pyrimethamine were found in all 
the 4 provinces. Combined resistance to 
chloroquine and amodiaquine, and to 
chloroquine, sufadoxine-pyrimethamine and 
amodiaquine were found in East Kalimantan 
and East Timor. Combined resistance to 
chloroquine and quinine, and to sulfadoxine- 
pyrimethamine and amodiaquine, and to 
chloroquine and sulfadoxine-pyrimethamine 
and quinine and amodiaquine and mefloquine 
were only found in East Kalimantan. Combined 
resistance to chloroquine and mefloquine was 
found only in East Timo8'-'"' (Table 22 and 
Table 23). 
In 1993, vivax malaria resistance to 
chloroquine and quinine was reported from a 
patient who acquired malaria from a blood 
transfusion in DKI-Jakarta (Table 22)". 
EFFICACY OF SEVERAL NEW 
ANTIMALARIAL DRUGS FOR 
TREATMENT 
Several clinical trials of new antimalarial 
drugs (mefloquine, halofantrine and artemisinin 
derivatives) have been performed for the 
treatment of falciparum malaria patients and 
vivax malaria patients in order to prepare 
alternative antimalarial drugs for possible fhture 
use. 
Table 22. Percentage of in-vitro P. falc';Parum and in-vivo P. vivax resistant to several 
(>I) antimalarial drugs in Indonesia, 1991 -1995'L~'1. 
CQ = Chloroquine 
SP = Sulfadoxine-Pynmetharnine 
Q = Quinine 
AQ = Arnodiaquine 
MQ = Mefloquine. 
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Table 23. In-vitro P. f a k i p ~ u r n ~  resistant to several (>I) antimalarial drugs in Indonesia, 
1991 - 19953s7~6'. 
* percent by total number of provinces (27) 
** percent by number of provinces tested. 
At a single oral dose of 750 mg (15 mg 
baselkg bw) mefloquine with or without 
sulfadoxine-pyrimethamine was shown to be 
effective and safe for the treatment of 
uncomplicated falciparum malaria resistant 
chloroquine as well as multidrug resistant cases. 
In studies conducted in the border areas of 
East Kalimantan and Irian Jaya, the parasite 
clearance rates were 94 - 100 %. Resistance at 
uncomplicated falciparum malaria had parasite 
clearance rates of 88 - 100 %. Resistance at 
level of late RI was found in East Kalimantan 
and North Sulawesi. Fever and parasite 
clearance times were 17 - 30 hours and 52 - 61 
hours respectively. In vivax malaria, parasite 
clearance rates were 95 - 100 %, the fever and 
parasite clearance times were 22 and 61 hours, 
respectively (Table 24)3'"M"."9. 
the level of RII and RIII was found only in Irian A total dose of 600 mg of artesunate given 
Jaya. Fever and parasite clearance times were 9 
- 25 hours and 47 - 59 hours, respectively as 200 mg loading dose followed by 100 mg 
pable 24)32.57.624. daily for 4 days was shown to be safe and 
effective for the treatment of uncomplicated 
Halofantrine at 500 mg (salt) 6 hourly for 
3 doses was shown to be effective and safe for 
the treatment of uncomplicated falcipanun 
malaria resistant to chloroquine as well as for 
the treatment of vivax malaria cases. 
Studies in East Kalimantan, North 
Sulawesi and Irian Jaya in patients with 
falciparum malaria in a multidrug resistance 
area using a 14 day evaluation. 
This artesunate trial was performed in East 
Kalimantan. The parasite clearance rate 
dropped to 60 % because of recrudescence after 
14 days following 100 % clearance at 14 days 
(late RI pattern) (days 21-28). The fever and 
parasite clearance times were 14 and 32 hours, 
respectively (Table 24)". 
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Table 24. Eificacy of several new antimalarial drugs for uncomplicated malaria in 
Indonesia, 1991 - 199532-'~s7~6'-9. 
Artemether 
Oral artemether at the total dose of 480 mg 
given as 160 mg loading dose followed by 80 
mg daily for 4 days was shown to be effective 
and safe for the treatment of uncomplicated 
in-vitro chloroquine resistance falciparum 
malaria. 
A study in Irian Jaya had a parasite 
clearance rate of 90 % with recrudescence (late 
RI pattern) (days 21-28). The fever and parasite 
clearance times were very fast, 8 and 29 hours, 
respectively (Table 24)67. 
EFFICACY O F  SEVERAL ANTIMALA- 
RIAL DRUGS FOR PROPHYLAXIS 
Several antimalarial drugs such as 
chloroquine, sulfadoxine-pyrimetharnine, pri- 
maquine, mefloquine and doxycycline were 
studied as prophylactic agents against malaria 
in 38 - 200 nonimmune transmigrants and 
soldiers in the hyperendemic areas of eastern 
Indonesia. 
Chloroquine 
Chloroquine is still used for malaria 
chemoprophylaxis in Indonesia. In East Timor 
and Irian Jaya, chloroquine 5 mg basekg bw 
weekly for 6 and 4 months, had protective 
efficacy of 93 % and 44 % respectively (Table 
2517%'. 
Sulfadoxine-pyrimethamine is not used for 
malaria chemoprophylaxis by the malaria 
control programme in Indonesia. In East Timor, 
sulfadoxine-pyrimethamine 1 tablet weekly for 
6 months had a protective eEcacy of 98 YO 
(Table 25)". 
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Table 25. Protective rates of several antimalarial drugs as chemoprophylaxis in 
Indonesia, 1981 - 199Sm. 
Rimaquine 
Primaquine could be used as a causal 
malaria prophylactic. However this drug is still 
not used for malaria chemoprophylaxis in 
Indonesia. In Irian Jaya, primaquine 0.5 mg 
basekg bw every other day or 0.5 mg basetkg 
bw daily for 16 - 52 weeks had a protective 
efficacy of 89 % and 92 % respectively (Table 
25)71-2. 
Mefloquine 
Mefloquine is a relatively new antimalarial 
drug and is not available in Indonesia. In Irian 
Jaya, mefloquine 250 mg base weekly following 
a loading dose of 250 mg base daily for 3 days, 
given for 13 weeks had a protective efficacy of 
100 % (Table 25)". 
In Indonesia, doxycycline is registered as 
an antibiotic. This drug is not used as an 
antimalarial drug by the malaria control 
programme. In Irian Jaya, doxycycline 100 mg 
daily for 13 weeeks had a protective efficacy of 
99 % (Table 25)73. 
SIDE-EFFECTS OF ANTIMALAFUAL 
DRUGS 
In the many antimalarial drug trials, the 
medications have usually been well tolerated at 
the dose given. 
Serious sideeffects of chloroquine have 
never been reported. Headache, dizziness, 
palpitation, itching, epigastric pain, abdominal 
pain, nausea, vomiting, and diarrhoea had been 
noted (Table 26)367.65.70. 
The most important sideeffect of sulfa- 
doxine-pyrimethamine is skin reaction (Steven 
Johnson syndrome). It had been reported from 
Irian Jaya. Itching, epigastric pain and rash 
were noted in East Timor (Table 26)70. 
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Table 26. Reported side-effects of several antimalarial drugs in Indonesia, 
1991 - 1995357,'.",659,7M 
Usually quinine is given as a life-saving 
drug in severe malaria patients. Only dizziness, 
tinitus and nausea have been reported (Table 
26)74. 
The sideeffects of primaquine when given 
alone as a chemoprophylactic were headache, 
epigastric pain, vomiting and diarrhoea (Table 
26)71-2. 
The common sideeffects of mefloquine 
reported were headache, dizziness, abdominal 
pain, nausea, diarrhoea and insomnia (Table 
26)63.73 
Abdominal pain, nausea, vomiting and 
diarrhoea were common side-effects of 
halofantrine. Also reported were dizziness, 
epistaxis and palpitation (Table 26)35-6.65.68-9. 
The sideeffects of oral and parentral 
artemether were abdominal pain and diarrhoea, 
while no sideeffects were noted in oral 
artesunate (Table 26)37.s7.74. 
DISCUSSION 
All the drug sensitivity tests were 
performed to confirm the P. falciparum and P. 
vivax resistant to chloroquine andfor other 
antimalarial drugs presence in Indonesia. These 
tests were mainly conducted in major foci of 
suspected chloroquine resistance. No follow up 
or continuing studies have been carried out. 
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Therefore findings are limited to these reported 
cases. However, this evaluation has confirmed 
resistance to chloroquine, sulfadoxine- 
pyrimethamine, quinine, amodiaquine and to 
several new antimalarial drugs (mefloquine and 
halofantrine) by P. falciparum (Table 27) and to 
chloroquine by P. vivax. 
Many mechanisms theoretically might 
induce changes in drug sensitivity of 
Plasmodium species, such as : physiological 
adaptation, selection among mixed sensitive and 
resistant parasite populations already present, 
spontaneous mutation and subsequent selection 
of resistance strains, and introduction of 
resistance transfer factors or plasmids7'. 
Subtherapeutic dosage is observed to be the 
most likely cause of increasingly resistant 
Plasmodium species in Indonesia. Subcurative 
blood levels of drug encourage the survival of 
tolerant strains of parasites. Evolution toward 
drug resistance may thereby be facilitated. 
This drug pressure has probably 
contributed heavily to the development of 
resistance in Indonesia. The first line and the 
most commonly available antimalarial drug in 
Indonesia is chloroquine. Chloroquine is 
retained in mosquito tissues after a blood 
meal is taken from a chloroquine-treated 
person. This exerts drug pressure on the 
sporogonic phase. 
Table 27. Cumulative number of province reporting .in-vbo and in-vivo resistant or 
recurrent to antimalarial drugs in Indonesia, 1981 - 1995. 
percent by total number of provinces (27) 
** percent by number of provinces tested. 
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Mutation may be one-step or multi-step, 
where total sensitivity is replaced by RIII 
resistant in one step or a series of mutations 
level to successively higher drug resistance 
levels. 
Antimalarial drugs should be distributed 
properly with one course of treatment per 
package and with clear information on drug 
administration to prevent inadequate treatment 
and to combat drug resistance. 
The emergence of chloroquine resistance, 
the unrelenting spread of RIII resistance and the 
presence of multidrug resistant falciparum 
malaria are important reasons to study the 
efficacy of several new antimalarial drugs. 
Mefloquine, halofantrine and artemisinin 
derivatives showed effectiveness and safety for 
treatment of uncomplicated falciparum malaria 
in chloroquine or multidrug resistant 
area$5-6,57,62-9 
. However, these drugs are 
expensive and still not available in Indonesia. 
This poses a continuing therapeutic challenge to 
improve the efficacy of drugs currently available 
by combination of several antimalaria drugs or 
other dnlgs such as antibiotics or adjustment of 
dosages. Additional studies are needed. 
Resistance of P.vivax to chloroquine is an 
emerging problem. Even though halofantrine 
was very effective in treating vivax malaria in 
P. vivax resistant areas@", no obvious 
replacement for chloroquine is presently 
available in Indonesia. Sulfadoxine-pyrime- 
thamine is not as effective as chloroquine in 
treating vivax malaria76. Quinine suffers from 
poor compliance and higher doses may be 
needed to cure the Chesson strain of P. vivax7'. 
The current time, retreatment of chloroquine 
resistant P. v i v a  with standard regimen of 
chloroquine 25 mg basekg bw for 3 days 
combined with primaquine 15 mg base daily for 
14 days, may be effective. If resistance remains, 
repeated treatment with chloroquine 10 mg 
basekg bw and primaquine 45 mg base, single 
dose, weekly for 12 weeks should be applied78. 
Chloroquine is no longer the drug of 
choice for both P. falciparum and P. vivax 
prophylaxis in Irian Jaya due to increasing 
levels of resistance in that area7'. Occurence of 
rare cases of Stevens-Johnson syndrome has 
limited the usefulness of sulfadoxine- 
pyrimethamine in prophylaxis70. However, 
although primaquine was shown very effective 
and safe as a causal prophylactic7'-', it is still 
not recommended because it has not been 
studied in large numbers of patients. 
Mefloquine was also shown to be very effective 
and safe7' but it is expensive and still not 
available in Indonesia. Doxycycline performs 
well as a prophylaxis, but there are 
contraindications for children and pregnant 
women7'. An alternative prophylactic drug 
which is safe and effective for children, 
pregnant and lactating women should also be 
studied, e.g. azithromycin. 
SUMMARY AND CONCLUCIONS 
Resistance to antimalarial drugs, especially 
chloroquine, has become a serious problem in 
case management throughout Indonesia. 
Appropriate baseline data and monitoring 
system for drug efficacy and resistance are 
required for reassessment and revision of 
national guidelines for malaria treatment. 
All studies of resistance of antimalarial 
drugs using in-vitro and in-vivo methods in 
Indonesia, were reviewed to determine the 
pattern of drug resistant malaria and to use this 
data to establish an effective monitoring system. 
Malaria treatment and prophylaxis, field and 
hospital based studies during the period 198 1 to 
1995 were included. 
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Resistance of P. falciparum to chloroquille 
was detected for the first time in East 
Kalimantan in 1973, and has spread to all (27) 
provinces at level of RI - RIII. Three provinces 
(West Java, Central Kalimantan and Bali) 
reported only in-vitro resistance, and 3 other 
provinces (West Sumatera, South Sumatera and 
DI-Yogyakarta) reported only in-vivo resistance, 
while in the other 21 provinces in-vitro and 
in-vivo resistance were detected. Currently, RIII 
resistance affects 20 provinces compared to 4 
provinces in 1981 - 1985. Chloroquine resistant 
vivax malaria has been detected since 1991 in 
Irian Jaya (41%), North Sumatera (13%), East 
Nusa Tenggara (8%), North Sulawesi (2%) and 
Jakarta (one case acquired by blood 
transfusion). 
The total number of provinces reporting P. 
falciparum resistance to sulfadoxine- 
pyrimethamine is 11 out of the 14 provinces 
undertaking testing. Seven provinces have only 
reported resistance by in-vitro test and the other 
4 provinces reported resistance by both in-vitro 
and in-vivo test at level of RI - RII. Of the 3 
provinces reporting no resistance, 2 provinces 
(Bengkulu and DKI-Jakarta) only conducted the 
in-vitro sensitivity test and 1 province 
(Southeast Sulawesi) only the in-vivo sensitivity 
test. 
Of the 12 provinces tested, only 6 
provinces (West Java, Central Java, East 
Kalimantan, East Nusa Tenggara, Central 
Sulawesi and Irian Jaya) show in-vitro P. 
falciparum resistance to quinine with 
resistant cases ranging from 3 to 100 %. 
After 1981-1985, 3 provinces that had 
reported resistance (West Java, Central Java 
and Irian Jaya) did not report any for 
the resistant cases. In East Kalirnantan 
where no resistance was present in 
1986-1990, in-vitro resistance was reported in 
1991-1995. 
Of the 5 provinces tested, 4 provinces 
(East Kalimantan, East Timor, South Sulawesi 
and Irian Jaya) had resistance to amodiaquine 
(12 - 100 %). Previously (1981-1985), no 
amodiaquine resistance was found in Irian Jaya. 
Of the 18 provinces tested, 5 provinces 
(Central Java, East Kalimantan, East Nusa 
Tenggara, East Timor and Irian Jaya) presented 
only in-vitro P. falciparum resistance to 
mefloquine (2 - 20 %). Central Java in 
1981-1985 and Irian Jaya in 1981-1990 
reported mefloquine resistance, but thereafter no 
resistance was detected, while East Nusa 
Tenggara reported mefloquine resistance in 
1986-1990 and East Kalimantan in 1991-1995. 
In-vitro P. falciparum multidrug resistance 
was found respectively in 84 %, 49 %, 40 % and 
11 % of cases in East Kalimantan, Irian Jaya, 
North Sulawesi and East Timor. Resistance to 
chloroquine and sulfadoxine-pyrimetharnine 
was found in all 4 provinces. Resistance to 
chloroquine and amodiaquine, and to 
chloroquine and sufadoxine-pyrimethamine and 
amodiaquine were found in East Kalimantan 
and East Timor. Resistance to chloroquine and 
quinine, to sulfadoxine-pyrimethamine and 
amdaquine, to chloroquine and sulfadoxine- 
pyrimethamine and quinine and amodiaquine 
and mefloquine were only found in East 
Kalimantan. Resistance to chloroquine and 
mefloquine was found only in East Timor 
At a single oral dose of 750 mg (15 mg 
basekg bw) mefloquine with or without 
sulfadoxine-pyrimethamine for the treatment of 
uncomplicated falcipamm malaria resulted in 
parasite clearance rates of 94 - 100 % in several 
studies in border areas of East Kalimantan and 
Irian Jaya. Resistance at level of MI and RIlI 
were found in Irian Jaya. Fever and parasite 
clearance times were 9 - 25 hours and 47 - 59 
hours, respectively. 
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Halofantrine at 500 mg (salt) 6 hourly !for 
3 doses for the trearnent of uncomplicated 
falciparum malaria in East Kalimantan, North 
Sulawesi and Irian Jaya had parasite clearance 
rates of 88 - 100 %. Resistances at level of late 
RI were found in East Kalimantan and North 
Sulawesi. Fever and parasite clearance times 
were 17 - 30 hours and 52 - 61 hours, 
respectively. In vivax malaria, parasite 
clearance rates were 95 - 100 %, the fever and 
parasite clearance times were 22 and 61 hours, 
respectively. 
A total dose of 600 mg of artesunate given 
as 200 mg loading dose followed by 100 mg 
daily for 4 days for the treatment of 
uncomplicated falciparum malaria in East 
Kalimantan, had parasite clearance rate 60 % 
with recrudescence (late RI pattern) on day 
21-28. The fever and parasite clearance times 
were 14 and 32 hours, respectively. 
Oral artemether at the total dose of 480 mg 
given as 160 mg loading dose with subsequent 
80 mg daily for 4 days for the treatment of 
uncomplicated falciparum malaria in Irian Jaya, 
had parasite clearance rate of 90 % with 
recrudescence (late RI pattern) on day 21-28. 
The fever and parasite clearance times were 
very fast, 8 and 29 hours, respectively. 
Studies on prophylaxis showed protection 
rates of respectively 41 % and 93 % to 
chloroquine in Irian Jaya and East Timor, 
sulfadoxine-pyrimethamine 98% in East Timor, 
primaquine 89-92% and doxycycline 99% and 
mefloquine 100% in Irian Jaya. 
The sideeffects of those antimalarial drugs 
were mostly mild. 
This evaluation confirms the existence of 
drug resistant P. falciparum and P. vivax in 
Indonesia. The unrelenting spread of RIII level 
resistance to chloroquine of falciparum malaria 
and the presence of multidrug resistant 
falciparum malaria are serious public health 
problems and pose a continuing therapeutic 
challenge. Chloroquine resistant vivax malaria 
is a newly emerging problem. The antimalarial 
drugs should be distributed properly for one 
course of treatment per package with clear 
information on drug administration to prevent 
inadequate treatment and combat drug 
resistance. Since new antimalarials are not 
available yet in Indonesia, the efficacy of drugs 
currently available (chloroquine, sulfadoxine- 
pyrimethamine, quinine and primaquine) 
should be studied, for example, in combination. 
Alternative prophylactic drugs (e.g 
azithromycin) which are safe and effective for 
children, pregnant and lactating women should 
also be considered. 
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